The biosimilar regulatory pathway

Paul Cornes

How is the use of a biosimilar approved? What do regulators look for? How do they guarantee their safety? Paul Cornes, MD from the University Hospital Bristol NHS Foundation Trust, Bristol, UK talks about the biosimilars regulatory pathway.

Share this video  
Similar topics
Related videos
11:24
The future of immunotherapy in multiple myeloma
Hearn Cho et al.
3:36
Retrospective multicenter analysis of venetoclax-treated CLL patients
Anthony Mato
4:36
IMPACT: a UK clinical trials programme for hemonc patients post-transplant
Charles Craddock
1:28
The role of pharmacists when introducing biosimilar monoclonal antibodies into practice
Simon Cheesman
1:56
Safety Profile of CAR-T Cell JCAR017 in R/R Aggressive B-NHL patients
David Maloney
More from Paul Cornes
Can the dream of affordable cancer care come true?
Why do we need biosimilars?
Are biosimilars similar enough?
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals